Delivery of nitric oxide with a nanocarrier promotes tumour vessel normalization and potentiates anti-cancer therapies
| العنوان: | Delivery of nitric oxide with a nanocarrier promotes tumour vessel normalization and potentiates anti-cancer therapies |
|---|---|
| المؤلفون: | Pei Ru Jin, Yi Chiung Hsu, Mei Ren Wang, Charles P. Lai, Anthony Yan-Tang Wu, Jane Wang, Fu Fei Hsu, Yunching Chen, Dong Yu Gao, Pei Lun Yu, John Jun Sheng Ko, Tsai-Te Lu, Chu Chi Lin, Li An Chu, Chih-Chun Chang, Jiantai Timothy Qiu, Yun Chieh Sung, Fu Nien Wang, Ann-Shyn Chiang, Show-Jen Chiou, Yu Sing Chen |
| المصدر: | Nature Nanotechnology. 14:1160-1169 |
| بيانات النشر: | Springer Science and Business Media LLC, 2019. |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | Male, Carcinoma, Hepatocellular, Angiogenesis, medicine.medical_treatment, Biomedical Engineering, Bioengineering, 02 engineering and technology, Nitric Oxide, 010402 general chemistry, 01 natural sciences, Nitric oxide, Neovascularization, Mice, chemistry.chemical_compound, Immune system, Adjuvants, Immunologic, Tumor Microenvironment, Animals, Humans, Medicine, General Materials Science, Electrical and Electronic Engineering, Neovascularization, Pathologic, business.industry, Liver Neoplasms, Cancer, Immunotherapy, 021001 nanoscience & nanotechnology, Condensed Matter Physics, medicine.disease, Atomic and Molecular Physics, and Optics, 0104 chemical sciences, chemistry, Delayed-Action Preparations, Cancer research, Nanoparticles, Cancer vaccine, Nanocarriers, medicine.symptom, 0210 nano-technology, business |
| الوصف: | Abnormal tumour vasculature has a significant impact on tumour progression and response to therapy. Nitric oxide (NO) regulates angiogenesis and maintains vascular homeostasis and, thus, can be delivered to normalize tumour vasculature. However, a NO-delivery system with a prolonged half-life and a sustained release mechanism is currently lacking. Here we report the development of NanoNO, a nanoscale carrier that enables sustained NO release to efficiently deliver NO into hepatocellular carcinoma. Low-dose NanoNO normalizes tumour vessels and improves the delivery and effectiveness of chemotherapeutics and tumour necrosis factor-related, apoptosis-inducing, ligand-based therapy in both primary tumours and metastases. Furthermore, low-dose NanoNO reprogrammes the immunosuppressive tumour microenvironment toward an immunostimulatory phenotype, thereby improving the efficacy of cancer vaccine immunotherapy. Our findings demonstrate the ability of nanoscale NO delivery to efficiently reprogramme tumour vasculature and immune microenvironments to overcome resistance to cancer therapy, resulting in a therapeutic benefit. |
| تدمد: | 1748-3395 1748-3387 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fbc6a29960fc5dc8726b07945d24e3fcTest https://doi.org/10.1038/s41565-019-0570-3Test |
| حقوق: | CLOSED |
| رقم الانضمام: | edsair.doi.dedup.....fbc6a29960fc5dc8726b07945d24e3fc |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 17483395 17483387 |
|---|